Insulin is the only medication that every person with type 1 diabetes needs, because the disease destroys the pancreatic cells that produce it. But the landscape of type 1 diabetes medication has expanded well beyond a single daily injection. Today it includes multiple categories of insulin with different speed profiles, automated pump systems that adjust doses in real time, non-insulin drugs that smooth out blood sugar swings, and even an immune-modulating therapy that can delay the disease before it fully develops. The choices have grown complex enough that understanding what is available, and what is coming, matters for anyone living with the condition.
Why Insulin Remains Non-Negotiable
Type 1 diabetes is an autoimmune disease in which the body’s immune cells infiltrate the insulin-producing beta cells in the pancreas and destroy them.1PubMed Central. The beta cell-immune cell interface in type 1 diabetes (T1D) Without insulin, glucose cannot enter most cells, and blood sugar spirals to dangerous levels. Unlike type 2 diabetes, where the body still makes some insulin and oral medications can coax cells into using it better, type 1 diabetes leaves people dependent on externally supplied insulin for survival. Every other medication discussed in this article works alongside insulin, not instead of it.
Basal and Bolus Insulin
The foundation of type 1 diabetes treatment is a “basal-bolus” regimen. Basal insulin provides a steady background level of the hormone around the clock, while bolus (mealtime) insulin handles the surges in blood sugar that follow eating. Basal insulins like glargine and degludec are designed to release slowly, keeping glucose stable between meals and overnight. Degludec, for instance, distributes its glucose-lowering effect almost evenly across each twelve-hour half of the day, regardless of whether you use a standard or concentrated formulation.2PubMed. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec That flat action profile reduces the risk of overnight low blood sugar.
Rapid-acting bolus insulins, such as lispro, aspart, and glulisine, are taken just before or at the start of a meal. They kick in within minutes and clear the bloodstream relatively fast, mimicking the sharp spike and fall of natural insulin release. Getting the dose right requires estimating how many carbohydrates you are about to eat and what your current blood sugar level is, which is where much of the day-to-day difficulty of type 1 management comes from.
Weekly Insulins on the Horizon
One of the most anticipated developments is basal insulin you inject only once a week. Two candidates have reached advanced clinical trials: insulin icodec and basal insulin Fc (BIF). The appeal is obvious. Cutting injections from seven per week to one could reduce treatment burden and improve adherence, particularly for people who struggle with daily routines.
However, the clinical data from type 1 diabetes trials are more cautious than the headlines suggest. A phase 3 trial comparing icodec to daily degludec in people with type 1 diabetes found that icodec was non-inferior for blood sugar control over 26 weeks. The catch was hypoglycemia: the rate of clinically significant or severe low blood sugar was roughly twice as high with icodec compared to degludec.3The Lancet. Once-weekly insulin icodec versus once-daily insulin degludec in individuals with type 1 diabetes (ONWARDS 6): a randomised, open-label, phase 3a trial A meta-analysis pooling data from multiple trials confirmed the pattern: daily insulin achieved slightly better HbA1c reduction, and weekly insulin was linked to more injection-site reactions and more serious adverse events.4PubMed Central. Once-Weekly Insulin Versus Once-Daily Insulin for Type 1 Diabetes Treatment: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
BIF, Eli Lilly’s weekly insulin, showed a similar profile. After 26 weeks it was non-inferior to degludec on HbA1c, and rates of hypoglycemia did not differ significantly. Fasting glucose was higher in the BIF group, though, and time in range was numerically lower.5Diabetes Care. Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes The bottom line for now is that weekly insulins look more promising in type 2 diabetes, where the residual insulin production provides a buffer. In type 1, the long duration of action makes it harder to fine-tune doses, and any excess insulin lingers for days rather than hours.
Automated Insulin Delivery Systems
Rather than replacing insulin with a different drug, closed-loop systems aim to make insulin delivery smarter. These setups pair a continuous glucose monitor with an insulin pump and an algorithm that automatically adjusts how much insulin the pump delivers. You still enter meal boluses in most current systems, which is why they are called “hybrid” closed-loop devices, but the algorithm handles basal adjustments on its own, responding to rising or falling glucose trends throughout the day and night.
The results are consistently strong. In a randomized crossover trial, an advanced hybrid closed-loop system increased time in range from about 58% to 70%, with the biggest improvement happening overnight.6Diabetes Care. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery Adolescents saw the largest gains compared to their baseline control. Across the broader literature, commercial hybrid closed-loop systems consistently improve blood sugar control relative to standard pump or injection therapy.7PubMed Central. Closed-loop insulin delivery: update on the state of the field and emerging technologies
A major recent milestone was the CIRCUIT trial, which tested closed-loop delivery in pregnant women with type 1 diabetes. Pregnancy demands extremely tight glucose control because high blood sugar raises the risk of complications for both mother and baby. The closed-loop group spent about 12.5 percentage points more time in the pregnancy-specific glucose range than the standard care group, while also spending less time in hypoglycemia and showing lower glucose variability.8JAMA. Closed-Loop Insulin Delivery in Type 1 Diabetes in Pregnancy: The CIRCUIT Randomized Clinical Trial For a population where even modest glucose improvements translate into meaningful clinical benefit, that gap is substantial.
Inhaled Insulin
Not all insulin has to go through a needle. Afrezza (Technosphere insulin) is an ultra-rapid-acting inhaled insulin powder approved for mealtime use in both type 1 and type 2 diabetes. You breathe it in through a small cartridge-based inhaler, and it reaches the bloodstream faster than any subcutaneous rapid-acting analogue. In a recent study, inhaled Technosphere insulin achieved peak glucose levels about 30 minutes earlier than a standard automated pump bolus, and the peak was lower.9PubMed Central. Safety and Efficacy of Inhaled Technosphere Insulin in the Postprandial Period With Modified Initial Dose Conversion
Because the insulin is absorbed through the lungs, the obvious question is whether it damages pulmonary tissue. A comprehensive safety review found that respiratory side effects were comparable between inhaled insulin and other treatments, with the exception of mild cough, which occurred in about 28% of Afrezza users versus 5% of comparators. Small, reversible declines in lung function were observed, but no serious pulmonary safety concerns emerged, including in a subgroup of patients with pre-existing lung issues.10PubMed Central. Comprehensive Pulmonary Safety Review of Inhaled Technosphere® Insulin in Patients with Diabetes Mellitus Inhaled insulin is not suitable for people with chronic lung diseases like asthma or COPD, and it requires periodic lung function testing. But for others, it offers an alternative to the pre-meal injection.
Pramlintide, the Forgotten Adjunct
Pramlintide (brand name Symlin) is the only non-insulin medication specifically approved by the FDA as an add-on for type 1 diabetes, and it remains vastly underused. It is a synthetic version of amylin, a hormone that healthy beta cells secrete alongside insulin. Because type 1 diabetes destroys those cells, people with the condition are deficient in amylin too. Pramlintide slows stomach emptying, suppresses the post-meal surge of glucagon, and promotes a feeling of fullness.
In a year-long controlled trial, adding pramlintide to insulin lowered HbA1c by about 0.3 percentage points more than placebo while also producing a small weight loss, compared to weight gain in the placebo group.11PubMed. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus Another trial showed a placebo-corrected HbA1c reduction of about half a percentage point at 13 weeks, with a sustained benefit through week 52 and no increase in the overall rate of severe hypoglycemia.12Diabetes Care. A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes A meta-analysis confirmed the pattern: lower HbA1c, reduced body weight, and lower total insulin doses, though nausea, vomiting, and appetite loss are common when starting the drug.13PubMed Central. Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis
The reason pramlintide is so rarely prescribed is practical. It requires separate injections before each meal, on top of the insulin you are already taking. That injection burden, combined with the gastrointestinal side effects and the modest HbA1c improvement, puts many people off. Research into longer-acting amylin analogues that could be co-formulated with insulin is ongoing and could change the equation.
SGLT2 Inhibitors and Ketoacidosis Risk
SGLT2 inhibitors like dapagliflozin and sotagliflozin work by blocking glucose reabsorption in the kidneys, causing excess sugar to be excreted in urine. They are widely used in type 2 diabetes, and there was considerable excitement about their potential in type 1. In a large trial, sotagliflozin lowered HbA1c by about 0.46 percentage points more than placebo, reduced weight by roughly 3 kg, and cut bolus insulin doses by about 3 units per day.14New England Journal of Medicine. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
The problem is diabetic ketoacidosis (DKA). A meta-analysis of 38 comparisons found that SGLT2 inhibitors roughly tripled the risk of DKA in people with type 1 diabetes. The risk was concentrated among those with higher body mass or markers of insulin resistance.15PLOS Medicine. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression A Lancet review estimated the risk more starkly, describing a roughly six-fold increase in DKA and projected that one extra case of ketoacidosis would occur for every 26 patient-years of exposure.16The Lancet Diabetes & Endocrinology. SGLT2 inhibitors as adjunctive therapy in type 1 diabetes DKA in the context of SGLT2 inhibitors is particularly insidious because blood sugar may be only mildly elevated, so neither the patient nor their glucose monitor flags the emergency in time. The FDA ultimately declined to approve SGLT2 inhibitors specifically for type 1 diabetes in the United States. In Europe, dapagliflozin was briefly authorized for type 1 use before being voluntarily withdrawn from that indication. Some clinicians still prescribe these drugs off-label for carefully selected patients, but it requires close monitoring and DKA education.
GLP-1 Receptor Agonists for Type 1 Diabetes
Drugs like semaglutide and liraglutide have reshaped the treatment of type 2 diabetes and obesity, so it is natural to wonder whether they help in type 1 as well. The short answer is that they are not approved for type 1, and the blood-sugar benefits are modest. Across studies, the HbA1c reduction has been minimal, in the range of 0 to 0.3 percentage points, partly because insulin doses tend to drop as the drug reduces appetite and slows digestion.17Medical Research Archives. Do GLP-1 receptor agonists have a place in the treatment of people with type 1 diabetes? Where GLP-1 drugs shine is weight loss, which ranged from about 2 to 7 kg depending on the specific agent. Semaglutide and tirzepatide produced the most pronounced reductions in both weight and insulin dose.
The growing prevalence of overweight and obesity among people with type 1 diabetes has increased interest in these drugs as adjuncts, since excess weight worsens insulin resistance and cardiovascular risk.18PubMed Central. Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer? The main concerns are hypoglycemia, which can increase if insulin doses are not proactively reduced, and the absence of long-term safety data in this population. Formal trials large enough to resolve these questions are underway.
Teplizumab and the Idea of Delaying Type 1 Diabetes
Most medications discussed so far manage blood sugar after the disease has fully developed. Teplizumab takes a fundamentally different approach. It is a monoclonal antibody that targets immune cells involved in the autoimmune attack on beta cells. In 2022 it became the first therapy approved by the FDA to delay the onset of clinical (stage 3) type 1 diabetes in people aged 8 and older who are in the preclinical (stage 2) phase, meaning they have autoantibodies and abnormal glucose tolerance but do not yet need insulin.19PubMed. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes
The distinction between delaying and preventing is important. Teplizumab pushes back the date at which a person becomes insulin-dependent, which is valuable in its own right, especially for children, but it does not stop the disease permanently in most cases. A broader meta-analysis of immunomodulatory treatments in type 1 diabetes found a paradox: these therapies preserved measurable beta cell function (as reflected by C-peptide, a marker of insulin production) without translating that preservation into better HbA1c.20PubMed Central. Immunomodulatory interventions in type 1 diabetes: a systematic review and meta-analysis revealing paradoxical dissociation between beta-cell preservation and glycemic control That disconnect suggests the remaining beta cells may not be producing enough insulin to move the needle on day-to-day glucose, or that external insulin dosing masks any small metabolic benefit.
Emergency Glucagon
Managing type 1 diabetes is not only about getting insulin in. It is also about having a plan for when too much insulin drives blood sugar dangerously low. Severe hypoglycemia can cause seizures, loss of consciousness, and death if untreated. The rescue drug is glucagon, which signals the liver to dump stored glucose into the bloodstream.
For decades, glucagon kits required mixing powder with liquid and injecting it, a daunting task for a bystander attending to someone who may be unconscious. Newer formulations have simplified this dramatically. Nasal glucagon is a dry powder sprayed into one nostril with no reconstitution, no injection, and no training beyond “point and press.” A randomized crossover study confirmed that intranasal glucagon was non-inferior to intramuscular injection for correcting insulin-induced hypoglycemia in adults with type 1 diabetes.21Diabetes Care. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study Pre-filled auto-injectors (similar in concept to an EpiPen) are also now available. Anyone who uses insulin should have a current glucagon product accessible, and the people around them should know where it is and how to use it.
Insulin During Pregnancy and Exercise
Two situations expose how sensitive insulin management really is: pregnancy and physical activity. During pregnancy, insulin requirements shift dramatically. They typically fall during the first trimester, then rise steeply through the second and into the third, before plateauing near term.22PubMed Central. Type 1 diabetes and pregnancy These changes happen on top of the already tight glucose targets needed to protect fetal development. As the CIRCUIT trial data showed, closed-loop systems can meaningfully improve time in range during pregnancy, which makes them an increasingly important tool for women planning to conceive.
Exercise creates the opposite problem. Physical activity generally increases insulin sensitivity, meaning that the same dose that was fine at rest may now cause low blood sugar. Simulation research has shown that adjusting insulin doses based on planned activity can significantly reduce time spent in hypoglycemia and improve time in range without increasing time spent high.23PubMed Central. Automatically Accounting for Physical Activity in Insulin Dosing for Type 1 Diabetes In practice, many people learn through trial and error to lower their bolus dose before exercise, set a temporary basal rate on their pump, or consume extra carbohydrates. The strategies vary depending on whether the activity is aerobic, anaerobic, or mixed, and the timing relative to meals adds another layer of complexity.
Biosimilar Insulins and Cost
Insulin is famously expensive in the United States, and cost is a real barrier to optimal management. Biosimilar insulins are follow-on products designed to closely replicate originator insulins without clinically meaningful differences in safety or effectiveness.24PubMed Central. Real world evidence of insulin and biosimilar insulin therapy-Opportunities to improve adherence, outcomes and cost-effectiveness Because the development costs are lower, biosimilars can be priced more affordably. Several biosimilar versions of glargine and lispro are now available, and their introduction has begun to put downward pressure on list prices. For people with type 1 diabetes who take insulin every day for their entire lives, even a modest per-vial savings compounds into a meaningful difference over time. The broader availability of biosimilars also matters in lower-income countries where originator insulin prices can be prohibitive.
Glucose-Responsive “Smart” Insulins
The ultimate goal in insulin research is an insulin molecule or delivery vehicle that activates only when blood sugar is high and goes dormant when glucose is normal. Such a system would essentially recreate the beta cell’s natural feedback loop in a chemical form. Three approaches are being explored: glucose-responsive polymer coatings that release encapsulated insulin when surrounding glucose rises, molecular modifications to the insulin itself that change its shape in the presence of glucose, and microneedle patches or hydrogels that combine a glucose sensor and an insulin reservoir in one device.25PubMed Central. ‘Smart’ insulin-delivery technologies and intrinsic glucose-responsive insulin analogues
Early protein-based systems that used enzymes like glucose oxidase to trigger insulin release showed proof of concept, but they struggle with stability, scalability, and the risk of immune reactions. Newer protein-free designs using synthetic materials like phenylboronic acid offer better long-term stability and are being tested in hydrogel and microneedle formats.26ACS Materials Au. Glucose-Responsive Materials for Smart Insulin Delivery: From Protein-Based to Protein-Free Design None of these approaches are close to clinical use yet, but the field has moved from theoretical to demonstrable in animal models, which puts it meaningfully closer than it was a decade ago.
Stem Cell Therapies and the Quest to Replace Beta Cells
If the core problem in type 1 diabetes is a missing cell type, the most direct fix would be to put those cells back. Transplanting insulin-producing cells derived from stem cells is an active area of research. In one approach, human stem cell-derived beta cells were loaded into a nanofibrous encapsulation device with an immunoprotective hydrogel core. In immunodeficient mice, the device reversed diabetes within a week and maintained glucose control for up to 120 days; in mice with intact immune systems, it lasted up to 60 days.27PubMed Central. A nanofibrous encapsulation device for safe delivery of insulin-producing cells to treat type 1 diabetes
The encapsulation strategy is critical because it addresses the central dilemma: without protection, transplanted cells get destroyed by the same autoimmune attack that caused the disease in the first place. Traditional islet transplantation from donor organs requires lifelong immunosuppressive drugs, which carry their own serious risks. Encapsulation devices and gene-edited “hypoimmune” stem cells are two strategies being developed to eliminate that need.28PubMed Central. Recent advances in stem cell-based therapies for type 1 diabetes: A glimpse into the future Human clinical trials of encapsulated and non-encapsulated stem cell-derived islets are underway at several companies, with early reports of patients achieving insulin independence for months at a time, though long-term durability and the need for repeated implants remain open questions.
The Psychological Side of Medication Burden
A medication landscape this complex exacts a psychological toll. Every meal requires a calculation, every workout demands a plan, and the consequences of getting it wrong can be immediate and frightening. Research in adolescents with type 1 diabetes has found that distress and fear of hypoglycemia predict poor adherence to correction dosing for high blood sugar.29Diabetes. Poor Adherence in Adolescents with Type 1 Diabetes Associated with Distress, Fear of Hypoglycemia, and Executive Functioning In other words, the fear of going too low can keep people from treating their highs, which over time drives up average blood sugar and increases the risk of complications. This is not a failure of willpower. It is a rational, if counterproductive, response to living with a condition where medication can itself become a threat. Addressing diabetes distress through mental health support is as clinically important as choosing the right insulin analogue, and it remains one of the most under-resourced parts of diabetes care.
Oral Insulin Research
Swallowing an insulin pill instead of injecting it has been a goal of pharmaceutical research for decades, and it remains frustratingly elusive. The stomach’s acidic environment degrades insulin before it can be absorbed, and the intestinal lining is not designed to let large protein molecules through. Researchers have tested a staggering variety of workarounds: nanoparticles, liposomes, hydrogels, mucoadhesive patches, ionic liquids, and microspheres. Some of these formulations significantly improve absorption compared to naked oral insulin, but none have achieved potency equivalent to a subcutaneous injection.30PubMed Central. A review on oral novel delivery systems of insulin through the novel delivery system formulations One promising approach uses an ionic liquid called CAGE, which simultaneously protects insulin from digestive enzymes, helps it cross the mucus layer, and opens tight junctions between intestinal cells to improve absorption.31PubMed Central. Recent Advances in Oral Insulin Delivery Technologies Oral insulin remains a research project rather than a clinical reality, but the practical impact of solving it, particularly for the billions of injections administered globally each year, keeps the field well funded.